The Largest Registry on the ACURATE neo Valve

Transcatheter aortic valve replacement (TAVR) using the ACURATE neo device depends, largely, on correct patient selection and appropriate oversizing. The individual anatomy of each patient, namely periannular and aortic root calcification, must be taken into account.

The ACURATE neo valve (Symetis/Boston, Ecublens, Switzerland) is a new-generation self-expanding valve characterized by a stent design shaped as an X and a unique release mechanism. This work analyzed technical and anatomical predictors for proper implantation of this device.

A total of 500 patients who underwent TAVR with the ACURATE neo valve were stratified according to landing zone calcification level (mild, moderate, or severe). Predictors of moderate or greater paravalvular leak and need for permanent pacemaker implantation were assessed.


Read also: Renal Impairment: How Does It Affect Angioplasty and Surgery?


Post-procedural moderate or greater paravalvular leak was more frequent with increasing device landing zone calcification (mild, 0.8% vs. moderate, 5.0% vs. severe, 13.0%; p < 0.001), while the need for permanent pacemaker implantation was independent of calcification.

The greater the periannular calcification (p < 0.001), the lesser the oversizing (p = 0.014), the higher the presence of annular plaque protrusions (p = 0.025), the greater the movement of the release system after full valve deployment (p = 0.02), and the higher the sinotubular junction height (p = 0.04). There was a higher rate of paravalvular insufficiency.


Read also: DEFENSE-PFO: High Risk PFO Closure Reduces Combined Events and Stroke Risk.


As regards predictors of permanent pacemaker implantation, there were no surprises compared with other studies or devices: pre-existing right bundle branch block and more oversizing.

Conclusion

Procedural success using the ACURATE neo device depends on appropriate oversizing and consideration of individual anatomy, mainly periannular and aortic root calcium distribution. To sum up, success depends on correct patient selection.

Original title: The ACURATE Neo Transcatheter Heart Valve. A Comprehensive Analysis of Predictors of Procedural Outcome.

Reference: Won-Keun Kim et al. J Am Coll Cardiol Intv 2018. Online before print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Su opinión nos interesa. Puede dejar su comentario, reflexión, pregunta o lo que desee aquí abajo. Será más que bienvenido.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...